Ensign Peak Advisors Inc Sells 3,180 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Posted by Defense World Staff on Mar 12th, 2023

Ensign Peak Advisors Inc reduced its position in Omnicell, Inc. (NASDAQ:OMCL – Get Rating) by 17.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,740 shares of the company’s stock after selling 3,180 shares during the period. Ensign Peak Advisors Inc’s holdings in Omnicell were worth $1,283,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of OMCL. MetLife Investment Management LLC boosted its holdings in shares of Omnicell by 55.4% in the 1st quarter. MetLife Investment Management LLC now owns 23,169 shares of the company’s stock valued at $3,000,000 after buying an additional 8,257 shares in the last quarter. Rhumbline Advisers raised its position in shares of Omnicell by 6.4% in the 1st quarter. Rhumbline Advisers now owns 111,098 shares of the company’s stock valued at $14,386,000 after purchasing an additional 6,657 shares during the last quarter. Great West Life Assurance Co. Can raised its position in shares of Omnicell by 0.4% in the 1st quarter. Great West Life Assurance Co. Can now owns 37,956 shares of the company’s stock valued at $5,036,000 after purchasing an additional 144 shares during the last quarter. Raymond James Trust N.A. raised its position in shares of Omnicell by 10.9% in the 1st quarter. Raymond James Trust N.A. now owns 3,881 shares of the company’s stock valued at $503,000 after purchasing an additional 382 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Omnicell by 0.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 848,688 shares of the company’s stock valued at $109,901,000 after purchasing an additional 4,839 shares during the last quarter.

Insider Activity

In other news, Director Joanne B. Bauer sold 13,115 shares of Omnicell stock in a transaction that occurred on Tuesday, March 7th. The shares were sold at an average price of $54.24, for a total transaction of $711,357.60. Following the completion of the transaction, the director now directly owns 28,096 shares of the company’s stock, valued at approximately $1,523,927.04. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Joanne B. Bauer sold 13,115 shares of Omnicell stock in a transaction on Tuesday, March 7th. The shares were sold at an average price of $54.24, for a total value of $711,357.60. Following the sale, the director now owns 28,096 shares of the company’s stock, valued at approximately $1,523,927.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Scott Peter Seidelmann sold 945 shares of Omnicell stock in a transaction on Tuesday, December 27th. The shares were sold at an average price of $48.28, for a total transaction of $45,624.60. Following the completion of the sale, the executive vice president now directly owns 29,788 shares in the company, valued at approximately $1,438,164.64. The disclosure for this sale can be found here. Insiders sold a total of 18,496 shares of company stock valued at $968,979 in the last three months. 2.76% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages recently commented on OMCL. StockNews.com raised shares of Omnicell from a “sell” rating to a “hold” rating in a research report on Friday, January 13th. Piper Sandler increased their price objective on shares of Omnicell from $55.00 to $66.00 and gave the company an “overweight” rating in a research report on Friday, January 27th. TheStreet lowered shares of Omnicell from a “c” rating to a “d+” rating in a research report on Tuesday, February 28th. SVB Leerink reissued a “market perform” rating on shares of Omnicell in a research report on Friday, January 27th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Omnicell from $140.00 to $57.00 and set a “neutral” rating for the company in a research report on Friday, November 18th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $71.67.

Omnicell Price Performance

NASDAQ:OMCL opened at $51.51 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.06 and a quick ratio of 1.71. The firm has a market cap of $2.32 billion, a price-to-earnings ratio of 515.10, a price-to-earnings-growth ratio of 5.64 and a beta of 0.89. The company has a 50 day moving average price of $54.87 and a 200-day moving average price of $65.37. Omnicell, Inc. has a 1-year low of $46.11 and a 1-year high of $138.50.

About Omnicell

(Get Rating)

Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.

Ensign Peak Advisors Inc Sells 3,180 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Insider Activity

Analyst Ratings Changes

Omnicell Price Performance

About Omnicell

See Also

You might be interested in: